Barres et al [42] reported altered promotor methylation of PDK4 in obese individuals, with the alteration being restored by significant weight loss, suggesting that empagliflozin protects against obesity-induced alterations in PDK4 expression upon WD feeding. Here, PDK4 is linked to obesity disorder.